文献速递哮喘

本瑞利珠单抗治疗重度嗜酸性哮喘:基于既往生物制剂使用与关键临床亚组的真实世界XALOC-1项目

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
PubMed 文献 · Eur Respir J · 2024-07-11

XALOC-1是一项大型多国回顾性真实世界研究,纳入1002例重度嗜酸性哮喘成人患者,评估本瑞利珠单抗治疗48周的年急性发作率、口服激素使用、症状控制和肺功能。结果显示总体急性发作率相对降低82.7%,既往生物制剂经治患者降低72.9%,且各关键临床特征亚组疗效一致。

要点

  • 本瑞利珠单抗治疗48周后71.3%患者无急性发作,基线仅17.2%。
  • 总体年急性发作率相对降低82.7%,既往生物制剂经治者降低72.9%。
  • 基线使用维持口服激素者中47.4%在48周时完全停用。

核心结论

  • 本瑞利珠单抗治疗重度嗜酸性哮喘患者,无论既往是否使用生物制剂及关键临床特征如何,临床结局均显著改善。

研究设计与样本

  • XALOC-1为大型多国回顾性观察性真实世界研究项目,纳入1002例重度嗜酸性哮喘成人患者,其中380例有既往生物制剂使用史。
  • 分析比较基线12个月与启动本瑞利珠单抗后至48周的年度急性发作率、维持口服激素使用、哮喘症状控制和肺功能。

主要发现

  • 第48周时71.3%患者无急性发作,基线时为17.2%。
  • 年度急性发作率总体相对降低82.7%,既往生物制剂经治患者相对降低72.9%,且在所有关键临床特征亚组中维持一致。
  • 基线使用维持口服激素的274例患者中,47.4%(130/274)在第48周完全停用;每日剂量平均较基线降低51.2%,既往生物制剂经治者(n=115)降低34.9%。
  • 观察到哮喘症状控制和肺功能具有临床意义的改善。

临床怎么用

  • 对于重度嗜酸性哮喘患者,本瑞利珠单抗可作为有效治疗选择,无论其既往是否使用过生物制剂。
  • 治疗可显著减少急性发作、帮助停用维持口服激素并改善症状与肺功能。

局限性

  • 本研究为回顾性观察性设计,未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pivotal phase 3 trials and real-world studies have demonstrated benralizumab's overall efficacy and safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed to confirm its real-world effectiveness in SEA according to previous biologic use and key baseline characteristics important for treatment selection. METHODS: XALOC-1 is a large, multinational, retrospective, observational, real-world study programme of benralizumab in adults with SEA. This 48-week integrated analysis assessed annualised exacerbation rate (AER), maintenance oral corticosteroid (mOCS) use, asthma symptom control and lung function during a 12-month baseline period and up to 48 weeks after benralizumab initiation. Subgroup analyses were based on previous biologic use and key baseline clinical characteristics (mOCS use, blood eosinophil count, exacerbation history, age at asthma diagnosis, fractional exhaled nitric oxide level and presence of atopy and chronic rhinosinusitis with nasal polyps). RESULTS: Out of 1002 patients analysed, 380 were biologic-experienced. At week 48, 71.3% were exacerbation-free (versus 17.2% at baseline); relative reduction in AER was 82.7% overall and 72.9% in biologic-experienced patients; rates were maintained across all key clinical characteristic subgroups. Of patients using mOCS at baseline (n=274), 47.4% (130 out of 274) eliminated their use by week 48; the mean reduction from baseline in daily dose was 51.2% and, notably, 34.9% in biologic-experienced patients (n=115). Clinically significant improvements in asthma symptom control and lung function were observed. CONCLUSION: In this large, real-world programme, SEA patients treated with benralizumab had substantial improvements in clinical outcomes irrespective of previous biologic use and key clinical characteristics important to therapeutic decision-making in clinical practice.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Jackson, Pelaia, Emmanuel, et al. Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. Eur Respir J. 2024. PMID: 38575162. doi:10.1183/13993003.01521-2023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。